2026 Yılında Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde İmmünoterapi: Yeni Tedavi Yaklaşımları ve Değişen Zorluklar

Yazarlar

Ali Türker

Özet

Erken evre rezektabl küçük hücreli dışı akciğer kanseri tedavisi, neoadjuvan ve perioperatif immünoterapinin kullanıma girmesiyle hızla değişmiştir. Faz III çalışmalar, platin temelli kemoterapiye PD-1/PD-L1 inhibitörlerinin eklenmesinin patolojik tam yanıt ve olaysız sağkalımı artırdığını, bazı çalışmalarda genel sağkalım kazanımı da sağladığını göstermiştir. Buna karşın neoadjuvan ve perioperatif stratejilerin göreli yeri, postoperatif immünoterapinin bağımsız katkısı, patolojik yanıt veya ctDNA/MRD ile tedavi yoğunluğunun uyarlanması, PD-L1 negatif hastalarda yararın büyüklüğü ve sınırda rezektabl hastalıkta konversiyon cerrahisinin rolü belirsizliğini korumaktadır. Bu bölüm, 2026 verileri ışığında adjuvan, neoadjuvan ve perioperatif immünoterapi kanıtlarını, FDA/EMA onay farklılıklarını, biyobelirteçleri ve cerrahiye ilişkin güncel tartışmaları gözden geçirmektedir.

Referanslar

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229–263. doi:10.3322/caac.21834.

Spiro SG, Silvestri GA. One hundred years of lung cancer. American Journal of Respiratory and Critical Care Medicine. 2005;172(5):523–529. doi:10.1164/rccm.200504-531OE.

Remon J, Cascone T, Saw SPL, et al. Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges. The Lancet Respiratory Medicine. 2026; doi:10.1016/S2213-2600(26)00221-3.

Rami-Porta R, Nishimura KK, Giroux DJ, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology. 2024;19(7):1007–1027. doi: 10.1016/j.jtho.2024.02.011.

Chouaid C, Danson S, Andreas S, et al. Adjuvant treatment patterns and outcomes in patients with stage IB–IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018;124:310–316. doi:10.1016/j.lungcan.2018.07.042.

Mitsudomi T, Sato K, Suda K, et al. Immunotherapy in resectable non–small cell lung cancer; emerging clinical questions. International Journal of Lung Cancer. 2026;1:100024. doi:10.1016/j.ijlcan.2026.100024.

Frumm SM, Florez N, Lee JM, et al. Updates on the perioperative management of resectable non–small cell lung cancer. Journal of the National Comprehensive Cancer Network. 2026;24(4):e267005. doi:10.6004/jnccn.2026.7005.

Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology. 2008;26:3552–3559. doi:10.1200/JCO.2007.13.9030.

NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. The Lancet. 2014;383(9928):1561–1571. doi:10.1016/S0140-6736(13)62159-5.

O’Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. The Lancet Oncology. 2022;23(10):1274–1286. doi:10.1016/S1470-2045(22)00518-6.

Goss GD, Darling GE, Westeel V, et al. Adjuvant durvalumab in completely resected early-stage non-small cell lung cancer. Journal of Clinical Oncology. 2026;44(7):553–564. doi:10.1200/JCO-25-01828.

Remon J, Cascone T, Peters S. BR.31 trial: adjuvant durvalumab as the third contender in resected non-small cell lung cancer. Journal of Clinical Oncology. 2026;44(7):518–522. doi:10.1200/JCO-25-02696.

Chaft JE, Sun Z, Rudin CM, et al. Adjuvant nivolumab vs observation in resected non-small cell lung cancer: a randomized clinical trial. JAMA. 2026; çevrimiçi yayımlanma: 1 Haziran. doi:10.1001/jama.2026.8992.

Provencio M, Bernabé R, Nadal E, et al. PL03.10 Adjuvant chemotherapy (CT) vs CT-immunotherapy for R0 stage IB–IIIA NSCLC patients (NADIM ADJUVANT): a randomized, phase 3 trial. Journal of Thoracic Oncology. 2025;20(10 Suppl 1):S6. doi:10.1016/j.jtho.2025.09.022.

Johnson DB, Nassar AH, Aijaz A, et al. Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization. Nature Reviews Clinical Oncology. 2026;23(5):341–355. doi:10.1038/s41571-026-01123-4.

Forde PM, Spicer J, Lu S, et al. neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. The New England Journal of Medicine. 2022;386:1973–1985. doi:10.1056/NEJMoa2202170.

Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. The New England Journal of Medicine. 2025;393:741–752. doi:10.1056/NEJMoa2502931.

Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. The New England Journal of Medicine. 2023;389:491–503. doi:10.1056/NEJMoa2302983.

Cascone T, Awad MM, Spicer JD, et al. Perioperative nivolumab in resectable lung cancer. The New England Journal of Medicine. 2024;390:1756–1769. doi:10.1056/NEJMoa2311926.

Heymach JV, He J, Harpole D, et al. Perioperative durvalumab for resectable non–small cell lung cancer: updated outcomes from the phase III AEGEAN trial. Journal of Clinical Oncology. 2026; çevrimiçi yayımlanma: 28 Ağustos. doi:10.1200/JCO-25-02659.

Yue D, Wang W, Liu H, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. The Lancet Respiratory Medicine. 2025;13(2):119–129. doi:10.1016/S2213-2600(24)00269-8.

Lu S, Zhang W, Wu L, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial. JAMA. 2024;331(3):201–211. doi:10.1001/jama.2023.24735.

Wakelee H, Spicer JD, Gao S, et al. Five-year outcomes of perioperative pembrolizumab for early-stage non-small-cell lung cancer from the randomized KEYNOTE-671 study. Annals of Oncology. Published online August 21, 2026. doi:10.1016/j.annonc.2026.08.005.

Cascone T, Awad MM, Spicer J, et al. Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: updated survival and biomarker analyses from CheckMate 77T. Journal of Clinical Oncology. 2025;43(17 Suppl):LBA8010. doi:10.1200/JCO.2025.43.17_suppl.LBA8010.

International Association for the Study of Lung Cancer. Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC. 12 September 2026. (28/09/2026 tarihinde https://www.iaslc.org/iaslc-news/press-release/perioperative-atezolizumab-plus-chemotherapy-more-doubles-event-free adresinden ulaşılmıştır).

Phillips WJ, Jackson A, Kidane B, et al. Immunotherapy for early-stage non–small cell lung cancer: a practical guide of current controversies. Clinical Lung Cancer. 2025;26(3):179-190. doi:10.1016/j.cllc.2025.01.006.

Forde PM, Peters S, Donington J, et al. Perioperative vs neoadjuvant nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816. Journal of Thoracic Oncology. 2024;19(10 Suppl):S2. doi:10.1016/j.jtho.2024.09.014.

Aburaki R, Fujiwara Y, Haketa S, et al. Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis. Journal of the National Cancer Institute. 2025;117(11):2191-2201. doi:10.1093/jnci/djaf190.

Yavuz G, Wang M, Spicer JD, et al. Navigating multimodality therapy in non–small cell lung cancer: neoadjuvant-only versus perioperative immunotherapy, surgical imperatives, and future approaches. American Society of Clinical Oncology Educational Book. 2026;46(3):e519336. doi:10.1200/EDBK-26-519336.

Dafni U, Tsourti Z, Vervita A, et al. neoadjuvant or perioperative chemoimmunotherapy treatment in patients with resectable NSCLC: still an open question. Comments on Marinelli et al. Journal of Thoracic Oncology. 2025;20(9):1336-1341. doi:10.1016/j.jtho.2025.05.007.

Garitaonaindia Y, Wakelee HA, Reck M, et al. Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer. Nature Reviews Clinical Oncology. 2026;23(9):712-729. doi:10.1038/s41571-026-01174-7.

Jones DR, Wakelee H, Spicer JD, et al. Association of pathologic regression with event-free survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage NSCLC. Journal of Thoracic Oncology. 2024;19(10 Suppl):S24-S25. doi:10.1016/j.jtho.2024.09.022.

Sorin M, Prosty C, Ghaleb L, et al. neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis. JAMA Oncology. 2024;10(5):621–633. doi:10.1001/jamaoncol.2024.0057.

Rossi G, Barcellini L, Tagliamento M, et al. Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses. ESMO Open. 2025;10(9):105759. doi:10.1016/j.esmoop.2025.105759.

Daly ME, Simone CB II, Redman MW, et al. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. The Lancet. 2026. Published online September 6, 2026. doi:10.1016/S0140-6736(26)01655-7.

Pircher A, Sótér S, Eaton M, et al. 117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): the randomized, double-blind, phase III KEYNOTE-867 study. Immuno-Oncology Technology. 2024;24(Suppl):100746. doi:10.1016/j.iotech.2024.100746.

Yayınlanan

16 Kasım 2026

Lisans

Lisans